Interdisciplinary cardiovascular and thoracic surgery · 2026
Impact of treatment-related complications on long-term outcomes in recurrence-free survivors with locally advanced non-small cell lung cancer after Trimodality therapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Okada Kazuhiro, Suzawa Ken, Aoyama Hideki, Ryuko Tsuyoshi, Nakajima Kumi, Yamamoto Haruchika, Tanaka Shin, Torigoe Hidejiro, Shien Kazuhiko, Miyoshi Kentaroh, Yoshio Kotaro, Okazaki Mikio, Sugimoto Seiichiro, Hiraki Takao, Soh Junichi, Toyooka Shinichi
Аннотация
OBJECTIVES: Trimodality therapy, consisting of induction chemoradiotherapy followed by surgery, remains a viable treatment option for locally advanced non-small cell lung cancer (LA-NSCLC). However, because this approach constitutes highly intensive local therapy, late adverse events may contribute to long-term, non-cancer-related outcomes. This study sought to clarify the prognostic impact of these events in recurrence-free patients treated with trimodality therapy.
METHODS: We conducted a retrospective analysis of patients who underwent trimodality therapy from January 1999 to December 2021 and remained recurrence-free during the follow-up.
RESULTS: Of the 199 patients who received trimodality therapy, 112 (56.3%) remained recurrence-free and were included in this analysis. Their median age at surgery was 62.5 years. The clinical stages were stage II (n = 27), stage III (n = 85). The median follow-up was 11.5 years, and the overall survival rates among patients without recurrence at 3, 5, and 10 years were 90.0%, 84.4%, and 71.5%, respectively. Multivariable analysis showed chronic lung injury extending beyond the anatomical segment (P = 0.04) was independent prognostic factors.
CONCLUSIONS: We observed an association between treatment-related pulmonary morbidity and long-term survival among recurrence-free patients after trimodality therapy. These findings suggest that minimizing treatment-related complications may be important for long-term outcomes.
METHODS: We conducted a retrospective analysis of patients who underwent trimodality therapy from January 1999 to December 2021 and remained recurrence-free during the follow-up.
RESULTS: Of the 199 patients who received trimodality therapy, 112 (56.3%) remained recurrence-free and were included in this analysis. Their median age at surgery was 62.5 years. The clinical stages were stage II (n = 27), stage III (n = 85). The median follow-up was 11.5 years, and the overall survival rates among patients without recurrence at 3, 5, and 10 years were 90.0%, 84.4%, and 71.5%, respectively. Multivariable analysis showed chronic lung injury extending beyond the anatomical segment (P = 0.04) was independent prognostic factors.
CONCLUSIONS: We observed an association between treatment-related pulmonary morbidity and long-term survival among recurrence-free patients after trimodality therapy. These findings suggest that minimizing treatment-related complications may be important for long-term outcomes.